1. Academic Validation
  2. Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents

Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents

  • Bioorg Med Chem Lett. 2009 Aug 1;19(15):4410-5. doi: 10.1016/j.bmcl.2009.05.052.
William Kemnitzer 1 Jared Kuemmerle Han-Zhong Zhang Shailaja Kasibhatla Ben Tseng John Drewe Sui Xiong Cai
Affiliations

Affiliation

  • 1 EpiCept Corporation, Inc. 6650 Nancy Ridge Drive, San Diego, CA 92121, USA.
Abstract

As a continuation of our efforts to discover and develop the 3-aryl-5-aryl-1,2,4-oxadiazole series of Apoptosis inducers as potential Anticancer agents, we explored substitutions at the 2- and 3-positions of the 3-aryl group to improve the aqueous solubility properties and identify development candidates. A small substitution such as methyl or hydroxymethyl at the 2-position was well tolerated. This modification, in combination with a 3-substituted furan ring as the 5-aryl group, resulted in 4g and 4h, which have improved solubility properties. Compound 4g was found to have good in vivo efficacy in animal studies via intravenous administration.

Figures